Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD

This article was originally published here

ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States.  It is characterized by the development of pathologic fluid-filled cysts

The post Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply